Emerging targets for combination therapy in melanomas

FEBS Letters

Volumn 589, Issue 22, 2015, Pages 3438-3448

  Saito, Renata De Freitas ^a   Tortelli, Tharcísio Citrângulo ^a   Jacomassi, Mayara D'Auria ^a   Otake, Andréia Hanada ^a   Chammas, Roger ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autophagy; Melanoma; Metabolic reprogramming; PAF; Tumor repopulation; Unfolded protein response

Indexed keywords

4 NEROLIDYLCATECHOL; AMBLYOMIN X; APAFANT; AZD 8055; BORTEZOMIB; CASPASE 3; CATECHOL DERIVATIVE; CISPLATIN; DACARBAZINE; ELESCLOMOL; FENRETINIDE; HYDROXYCHLOROQUINE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHENFORMIN; PROTEINASE INHIBITOR; SELUMETINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT;

AEROBIC METABOLISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; ENDOPLASMIC RETICULUM STRESS; EXOSOME; HUMAN; IMMUNOGENICITY; MELANOMA; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR GROWTH; UNFOLDED PROTEIN RESPONSE; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY;

EID: 84946237396     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2015.09.022     Document Type: Review

References (130)

1. J.J. Luke, and G.K. Schwartz Chemotherapy in the management of advanced cutaneous malignant melanoma Clin. Dermatol. 31 2013 290 297
2. P.B. Chapman, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
3. M.K. Callahan, and J.D. Wolchok At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy J. Leukoc. Biol. 94 2013 41 53
4. A.M. Intlekofer, and C.B. Thompson At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy J. Leukoc. Biol. 94 2013 25 39
5. J. Larkin, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 373 2015 23 34
6. F.S. Hodi, and et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma Cancer Immunol. Res. 2 2014 632 642
7. G.A. de Souza, and et al. Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation Proteomics 6 2006 1460 1470
8. V.K. Hill, J.J. Gartner, Y. Samuels, and A.M. Goldstein The genetics of melanoma: recent advances Annu. Rev. Genomics Hum. Genet. 14 2013 257 279
9. M.A. Cotter, and et al. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice Clin. Cancer Res. 13 2007 5952 5958
10. A.G. Goodson, M.A. Cotter, P. Cassidy, M. Wade, S.R. Florell, T. Liu, K.M. Boucher, and D. Grossman Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention Clin. Cancer Res. 15 2009 7434 7440
11. X. Qu, and et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene J. Clin. Invest. 112 2003 1809 1820
12. M.C. Maiuri, E. Tasdemir, A. Criollo, E. Morselli, J.M. Vicencio, R. Carnuccio, and G. Kroemer Control of autophagy by oncogenes and tumor suppressor genes Cell Death Differ. 16 2009 87 93
13. R. Mathew, V. Karantza-Wadsworth, and E. White Role of autophagy in cancer Nat. Rev. Cancer 7 2007 961 967
14. H. Liu, Z. He, T. von Rütte, S. Yousefi, R.E. Hunger, and H.U. Simon Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma Sci. Transl. Med. 5 2013 202ra123
15. H. Liu, Z. He, and H.U. Simon Autophagy suppresses melanoma tumorigenesis by inducing senescence Autophagy 10 2014 372 373
16. Z. Yue, S. Jin, C. Yang, A.J. Levine, and N. Heintz Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor Proc. Natl. Acad. Sci. USA 100 2003 15077 15082
17. X.H. Liang, L.K. Kleeman, H.H. Jiang, G. Gordon, J.E. Goldman, G. Berry, B. Herman, and B. Levine Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein J. Virol. 72 1998 8586 8596
18. M. Elgendy, and S. Minucci A novel autophagy-independent, oncosuppressive function of BECN1: degradation of MCL1 Autophagy 11 2015 581 582
19. Y. Hara, and M. Nakamura Overexpression of autophagy-related beclin-1 in advanced malignant melanoma and its low expression in melanoma-in-situ Eur. J. Dermatol. 22 2012 128 129
20. R. Lazova, R.L. Camp, V. Klump, S.F. Siddiqui, R.K. Amaravadi, and J.M. Pawelek Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome Clin. Cancer Res. 18 2012 370 379
21. H. Maes, S. Martin, T. Verfaillie, and P. Agostinis Dynamic interplay between autophagic flux and Akt during melanoma progression in vitro Exp. Dermatol. 23 2014 101 106
22. X.H. Ma, S. Piao, D. Wang, Q.W. McAfee, K.L. Nathanson, J.J. Lum, L.Z. Li, and R.K. Amaravadi Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma Clin. Cancer Res. 17 2011 3478 3489
23. R. Rangwala, and et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Autophagy 10 2014 1369 1379
24. R. Rangwala, and et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma Autophagy 10 2014 1391 1402
25. J.L. Armstrong, and et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition Clin. Cancer Res. 17 2011 2216 2226
26. X.H. Ma, and et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma J. Clin. Invest. 124 2014 1406 1417
27. C.M. Kenific, and J. Debnath Cellular and metabolic functions for autophagy in cancer cells Trends Cell Biol. 25 2015 37 45
28. F.J. Stevens, and Y. Argon Protein folding in the ER Semin. Cell Dev. Biol. 10 1999 443 454
29. D.N. Hebert, and M. Molinari In and out of the ER: protein folding, quality control, degradation, and related human diseases Physiol. Rev. 87 2007 1377 1408
30. A.M. Fourie, J.F. Sambrook, and M.J. Gething Common and divergent peptide binding specificities of hsp70 molecular chaperones J. Biol. Chem. 269 1994 30470 30478
31. L. Ellgaard, and L.W. Ruddock The human protein disulphide isomerase family: substrate interactions and functional properties EMBO Rep. 6 2005 28 32
32. P. Malkus, F. Jiang, and R. Schekman Concentrative sorting of secretory cargo proteins into COPII-coated vesicles J. Cell Biol. 159 2002 915 921
33. M.H. Smith, H.L. Ploegh, and J.S. Weissman Road to ruin: targeting proteins for degradation in the endoplasmic reticulum Science 334 2011 1086 1090
34. A. Bertolotti, Y. Zhang, L.M. Hendershot, H.P. Harding, and D. Ron Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response Nat. Cell Biol. 2 2000 326 332
35. C.Y. Liu, M. Schröder, and R.J. Kaufman Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum J. Biol. Chem. 275 2000 24881 24885
36. K. Kohno How transmembrane proteins sense endoplasmic reticulum stress Antioxid. Redox Signal. 9 2007 2295 2303
37. R.C. Wek, and D.R. Cavener Translational control and the unfolded protein response Antioxid. Redox Signal. 9 2007 2357 2371
38. H.P. Harding, I. Novoa, Y. Zhang, H. Zeng, R. Wek, M. Schapira, and D. Ron Regulated translation initiation controls stress-induced gene expression in mammalian cells Mol. Cell 6 2000 1099 1108
39. Y. Ma, and L.M. Hendershot Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress J. Biol. Chem. 278 2003 34864 34873
40. E. Kojima, and et al. The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress: elucidation by GADD34-deficient mice FASEB J. 17 2003 1573 1575
41. H. Zinszner, M. Kuroda, X. Wang, N. Batchvarova, R.T. Lightfoot, H. Remotti, J.L. Stevens, and D. Ron CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum Genes Dev. 12 1998 982 995
42. H. Puthalakath, and et al. ER stress triggers apoptosis by activating BH3-only protein Bim Cell 129 2007 1337 1349
43. K.D. McCullough, J.L. Martindale, L.O. Klotz, T.Y. Aw, and N.J. Holbrook Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state Mol. Cell. Biol. 21 2001 1249 1259
44. W. B'chir, and et al. The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression Nucleic Acids Res. 41 2013 7683 7699
45. J.H. Lin, and et al. IRE1 signaling affects cell fate during the unfolded protein response Science 318 2007 944 949
46. J. Hollien, and J.S. Weissman Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response Science 313 2006 104 107
47. K. Haze, T. Okada, H. Yoshida, H. Yanagi, T. Yura, M. Negishi, and K. Mori Identification of the G13 (cAMP-response-element-binding protein-related protein) gene product related to activating transcription factor 6 as a transcriptional activator of the mammalian unfolded protein response Biochem. J. 355 2001 19 28
48. H. Yoshida, T. Matsui, A. Yamamoto, T. Okada, and K. Mori XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor Cell 107 2001 881 891
49. Y. Ma, and L.M. Hendershot The role of the unfolded protein response in tumour development: friend or foe? Nat. Rev. Cancer 4 2004 966 977
50. M. Wang, and R.J. Kaufman The impact of the endoplasmic reticulum protein-folding environment on cancer development Nat. Rev. Cancer 14 2014 581 597
51. M.P. Mattson Hormesis defined Ageing Res. Rev. 7 2008 1 7
52. B. Mollereau, S. Manié, and F. Napoletano Getting the better of ER stress J. Cell Commun. Signal. 8 2014 311 321
53. N.S. Chitnis, and et al. miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner Mol. Cell 48 2012 353 364
54. A.L. Huber, and et al. p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose Mol. Cell 49 2013 1049 1059
55. S.B. Cullinan, and J.A. Diehl PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress J. Biol. Chem. 279 2004 20108 20117
56. L.S. Hart, and et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth J. Clin. Invest. 122 2012 4621 4634
57. A.S. Lee GRP78 induction in cancer: therapeutic and prognostic implications Cancer Res. 67 2007 3496 3499
58. P. Tschandl, A.S. Berghoff, M. Preusser, S. Burgstaller-Muehlbacher, H. Pehamberger, I. Okamoto, and H. Kittler NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi PLoS One 8 2013 e69639
59. N. Dhomen, and et al. Oncogenic braf induces melanocyte senescence and melanoma in mice Cancer Cell 15 2009 294 303
60. C. Michaloglou, and et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi Nature 436 2005 720 724
61. C. Denoyelle, and et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway Nat. Cell Biol. 8 2006 1053 1063
62. P. Hersey, and X.D. Zhang Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma Pigm. Cell Melanoma Res. 21 2008 358 367
63. L. Zhuang, R.A. Scolyer, C.S. Lee, S.W. McCarthy, W.A. Cooper, X.D. Zhang, J.F. Thompson, and P. Hersey Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma Histopathology 54 2009 462 470
64. C.C. Jiang, and et al. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response Cancer Res. 67 2007 5880 5888
65. K.H. Tay, Q. Luan, A. Croft, C.C. Jiang, L. Jin, X.D. Zhang, and H.Y. Tseng Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress Cell. Signal. 26 2014 287 294
66. C.C. Jiang, L.H. Chen, S. Gillespie, Y.F. Wang, K.A. Kiejda, X.D. Zhang, and P. Hersey Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis Cancer Res. 67 2007 9750 9761
67. L.H. Chen, C.C. Jiang, R. Watts, R.F. Thorne, K.A. Kiejda, X.D. Zhang, and P. Hersey Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein Cancer Res. 68 2008 834 842
68. Y.F. Wang, C.C. Jiang, K.A. Kiejda, S. Gillespie, X.D. Zhang, and P. Hersey Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1 Clin. Cancer Res. 13 2007 4934 4942
69. C.C. Jiang, and et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress Cancer Res. 68 2008 6708 6717
70. C.C. Jiang, D. Wroblewski, F. Yang, P. Hersey, and X.D. Zhang Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax Neoplasia 11 2009 945 955
71. A. Croft, and et al. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress J. Invest. Dermatol. 134 2014 488 497
72. D. Beck, and et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells Sci. Signal. 6 2013 ra7
73. P.E. Lovat, and et al. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress Cancer Res. 68 2008 5363 5369
74. M. Zanetti Cell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells Ann. NY. Acad. Sci. 1284 2013 6 11
75. D.V. Krysko, A.D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele Immunogenic cell death and DAMPs in cancer therapy Nat. Rev. Cancer 12 2012 860 875
76. M. Obeid, and et al. Ecto-calreticulin in immunogenic chemotherapy Immunol. Rev. 220 2007 22 34
77. I. Martins, and et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress Oncogene 30 2011 1147 1158
78. C.N. Roybal, S. Yang, C.W. Sun, D. Hurtado, D.L. Vander Jagt, T.M. Townes, and S.F. Abcouwer Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4 J. Biol. Chem. 279 2004 14844 14852
79. J. Ikeda, S. Kaneda, K. Kuwabara, S. Ogawa, T. Kobayashi, M. Matsumoto, T. Yura, and H. Yanagi Cloning and expression of cDNA encoding the human 150 kDa oxygen-regulated protein, ORP150 Biochem. Biophys. Res. Commun. 230 1997 94 99
80. C. Hetz, E. Chevet, and H.P. Harding Targeting the unfolded protein response in disease Nat. Rev. Drug Discovery 12 2013 703 719
81. A.H. Schönthal Pharmacological targeting of endoplasmic reticulum stress signaling in cancer Biochem. Pharmacol. 85 2013 653 666
82. A.M. Chudzinski-Tavassi, and et al. A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system Toxicon 56 2010 1145 1154
83. D.A. Maria, and et al. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production Invest. New Drugs 31 2013 493 505
84. C.A. Brohem, and et al. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death Pigm. Cell Melanoma Res. 25 2012 354 369
85. D. Ravindran Menon, and et al. A stress-induced early innate response causes multidrug tolerance in melanoma Oncogene 2014
86. A. Roesch, B. Becker, S. Meyer, P. Wild, C. Hafner, M. Landthaler, and T. Vogt Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas Mod. Pathol. 18 2005 1249 1257
87. A. Roesch, and et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells Cancer Cell 23 2013 811 825
88. J.H. Nijwening, E.J. Geutjes, R. Bernards, and R.L. Beijersbergen The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence PLoS One 6 2011 e25235
89. P. Yuan, and et al. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma Proc. Natl. Acad. Sci. USA 110 2013 18226 18231
90. M. Cierlitza, and et al. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations Exp. Dermatol. 24 2015 155 157
91. A. Roesch, and et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth Cell 141 2010 583 594
92. D.P. Kelly, and R.C. Scarpulla Transcriptional regulatory circuits controlling mitochondrial biogenesis and function Genes Dev. 18 2004 357 368
93. F. Vazquez, and et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress Cancer Cell 23 2013 287 301
94. R. Haq, and et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF Cancer Cell 23 2013 302 315
95. J.H. Lim, C. Luo, F. Vazquez, and P. Puigserver Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization Cancer Res. 74 2014 3535 3545
96. Y.N. Gopal, and et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma Cancer Res. 74 2014 7037 7047
97. J.J. Kim, and I.F. Tannock Repopulation of cancer cells during therapy: an important cause of treatment failure Nat. Rev. Cancer 5 2005 516 525
98. P. Martin, D. D'Souza, J. Martin, R. Grose, L. Cooper, R. Maki, and S.R. McKercher Wound healing in the PU.1 null mouse-tissue repair is not dependent on inflammatory cells Curr. Biol. 13 2003 1122 1128
99. F. Li, Q. Huang, J. Chen, Y. Peng, D.R. Roop, J.S. Bedford, and C.Y. Li Apoptotic cells activate the "phoenix rising" pathway to promote wound healing and tissue regeneration Sci. Signal. 3 2010 ra13
100. C.D. Gregory, and J.D. Pound Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues J. Pathol. 223 2011 177 194
101. A.L. Donato, Q. Huang, X. Liu, F. Li, M.A. Zimmerman, and C.Y. Li Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy J. Invest. Dermatol. 134 2014 1686 1692
102. Q. Huang, and et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy Nat. Med. 17 2011 860 866
103. V. Melnikova, and M. Bar-Eli Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor Cancer Metastasis Rev. 26 2007 359 371
104. M. Darst, M. Al-Hassani, T. Li, Q. Yi, J.M. Travers, D.A. Lewis, and J.B. Travers Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line J. Immunol. 172 2004 6330 6335
105. K. Heon Seo, H.M. Ko, H.A. Kim, J.H. Choi, S. Jun Park, K.J. Kim, H.K. Lee, and S.Y. Im Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation Cancer Res. 66 2006 4681 4686
106. R.P. Sahu, M. Ferracini, and J.B. Travers Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists Mediators Inflamm. 2015 2015 820543
107. A.C. Onuchic, C.M. Machado, R.F. Saito, F.J. Rios, S. Jancar, and R. Chammas Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma Mediators Inflamm. 2012 2012 175408
108. S.I. de Oliveira, and et al. Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy BMC Cancer 10 2010 200
109. V.A. Fadok, D.L. Bratton, and P.M. Henson Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences J. Clin. Invest. 108 2001 957 962
110. M. Correa, J. Machado, C.R. Carneiro, J.B. Pesquero, M. Bader, L.R. Travassos, R. Chammas, and M.G. Jasiulionis Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth Int. J. Cancer 114 2005 356 363
111. A.L. Bachi, L.C. Dos Santos, S. Nonogaki, S. Jancar, and M.G. Jasiulionis Apoptotic cells contribute to melanoma progression and this effect is partially mediated by the platelet-activating factor receptor Mediators Inflamm. 2012 2012 610371
112. M. Ferracini, F.J. Rios, M. Pecenin, and S. Jancar Clearance of apoptotic cells by macrophages induces regulatory phenotype and involves stimulation of CD36 and platelet-activating factor receptor Mediators Inflamm. 2013 2013 950273
113. S. Jancar, and R. Chammas PAF receptor and tumor growth Curr. Drug Targets 15 2014 982 987
114. M.M. Koga, B. Bizzarro, A. Sá-Nunes, F.J. Rios, and S. Jancar Activation of PAF-receptor induces regulatory dendritic cells through PGE2 and IL-10 Prostaglandins Leukot. Essent. Fatty Acids 89 2013 319 326
115. M.A. Antonyak, and R.A. Cerione Microvesicles as mediators of intercellular communication in cancer Methods Mol. Biol. 1165 2014 147 173
116. L.G. Lima, R. Chammas, R.Q. Monteiro, M.E. Moreira, and M.A. Barcinski Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner Cancer Lett. 283 2009 168 175
117. S.M. van Dommelen, P. Vader, S. Lakhal, S.A. Kooijmans, W.W. van Solinge, M.J. Wood, and R.M. Schiffelers Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery J. Control. Release 161 2012 635 644
118. S. Jia, and et al. Emerging technologies in extracellular vesicle-based molecular diagnostics Expert Rev. Mol. Diagn. 14 2014 307 321
119. D. Xiao, and et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes PLoS One 7 2012 e46874
120. E.U. Wieckowski, C. Visus, M. Szajnik, M.J. Szczepanski, W.J. Storkus, and T.L. Whiteside Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes J. Immunol. 183 2009 3720 3730
121. S. Yu, and et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells J. Immunol. 178 2007 6867 6875
122. K. Al-Nedawi, B. Meehan, J. Micallef, V. Lhotak, L. May, A. Guha, and J. Rak Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells Nat. Cell Biol. 10 2008 619 624
123. T. Chen, J. Guo, M. Yang, X. Zhu, and X. Cao Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine J. Immunol. 186 2011 2219 2228
124. E.J. Ekström, C. Bergenfelz, V. von Bülow, F. Serifler, E. Carlemalm, G. Jönsson, T. Andersson, and K. Leandersson WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells Mol. Cancer 13 2014 88
125. A. Marton, and et al. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro Immunol. Lett. 148 2012 34 38
126. C. Federici, and et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin PLoS One 9 2014 e88193
127. G.K. Alderton Metastasis. Exosomes drive premetastatic niche formation Nat. Rev. Cancer 12 2012 447
128. J.L. Hood, R.S. San, and S.A. Wickline Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis Cancer Res. 71 2011 3792 3801
129. H. Peinado, and et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET Nat. Med. 18 2012 883 891
130. L.G. Lima, and et al. Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles Thromb. Haemost. 106 2011 712 723